Compare Gogoro Inc (GGR) vs Globus Medical Inc. Class A Common Stock (GMED) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gogoro Inc vs Globus Medical Inc. Class A Common Stock — how do they compare? Gogoro Inc trades at $2.75 (market cap $65.04M), while Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B). The key difference: Globus Medical Inc. Class A Common Stock is far larger — about 157.6× Gogoro Inc's market cap, and Globus Medical Inc. Class A Common Stock is trading nearer its 52-week high, Gogoro Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Gogoro Inc for 14 Days and Globus Medical Inc. Class A Common Stock for 0 Days on average.
| GGR | GMED | |
|---|---|---|
Market Cap | $65.04M | $10.25B |
Volume | 21,493 | 1,108,124 |
Sector | Consumer Cyclical | Health |
52-Week High | $4.66 | $96.82 |
52-Week Low | $2.20 | $58.33 |
Typical Hold Time | 14 Days | 0 Days |
Enterprise Value | $351.48M | $9.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GGR trades at $3.24, up 2.53% with a bullish technical signal despite negative profitability metrics. The company reported $281.48M revenue for 2025 but a net loss of $79.97M, though losses are projected to narrow in 2026. Recent developments include $61.8M in new equity investments and board appointments to strengthen governance. Technical indicators show bullish momentum with support at $3.00.
While technical momentum appears positive, fundamental challenges persist with negative margins and cash flow. The investment case hinges on Gogoro's ability to achieve profitability amid expansion costs. Analyst consensus remains cautious with 100% hold ratings, suggesting investors await clearer profitability signals before committing.
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gogoro Inc
Gogoro is a global technology leader in battery-swapping ecosystems for electric two-wheelers. It provides smart, sustainable urban mobility solutions and manages an extensive network of battery stations.
Read more on GGR →About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →
